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Abstract Telomerase activity is essential for the continued
growth and survival of malignant cells, therefore inhibition
of this activity presents an attractive target for anti-cancer
therapy. The telomerase inhibitor GRN163L, was shown to
inhibit the growth of cancer cells both in vitro and in vivo.
Mesenchymal stem cells (MSCs) also show telomerase
activity in maintaining their self-renewal; therefore the
effects of telomerase inhibitors on MSCs may be an issue
of concern. MSCs are multipotent cells and are important
for the homeostasis of the organism. In this study, we
sought to demonstrate in vitro effects of GRN163L on rat
MSCs. When MSCs were treated with 1 µM GRN163L,
their phenotype changed from spindle-shaped cells to
rounded ones and detached from the plate surface, similar
to cancer cells. Quantitative-RT-PCR and immunoblotting
results revealed that GRN163L holds MSCs at the G1 state
of the cell cycle, with a drastic decrease in mRNA and
protein levels of cyclin D1 and its cdk counterparts, cdk4
and cdk6. This effect was not observed when MSCs were
treated with a mismatch control oligonucleotide. One week
after GRN163L was removed, mRNA and protein expres-
sions of the genes, as well as the phenotype of MSCs
returned to those of untreated cells. Therefore, we conclud-
ed that GRN163L does not interfere with the self-renewal
and differentiation of MSCs under short term in vitro
culture conditions. Our study provides additional support
for treating cancers by administrating GRN163L without
depleting the body’s stem cell pools.
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Introduction
Telomerase is a ribonucleoprotein complex consisting of a
reverse transcriptase catalytic subunit (hTERT) and an
RNA moiety (hTR or hTERC). The template region of
hTR is complementary to telomeric DNA and together with
hTERT elongates telomeres by adding TTAGGG repeats to
the end of the chromosome. This leads to stabilization of
telomere lengths, prevention of t-loop and overhang loss,
and continued cell division [1, 2]. Telomerase activity is
reduced or absent in majority of normal tissues, which leads
to a progressive shortening of the telomere with each cell
division. In contrast, tumor cells and self-renewable tissues
express telomerase to sustain their growth. The presence of
this activity in many different kinds of human tumors, but
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not in normal somatic cells, makes inhibition of telomerase
activity an attractive tool on targeted cancer therapy [3–5].
Experimental studies based on anti-telomerase cancer
therapies, such as immunotherapy, gene therapy, small
molecule inhibitors and oligonucleotide-based therapeutics
[3–5] have been making progress in recent years. A novel
human telomerase RNA (hTR) antagonist GRN163L (Ime-
telstat) is a lipid-modified N3′→P5′ thio-phosphoramidate
that is complementary to the template region of hTR,
preventing it from binding to the telomeric repeats. The
GRN163L sequence (5′-Palm-TAGGGTTAGACAA-3′) is
apparently unique in the human transcriptome, and shows
greatly enhanced stability as well as specific and high-
affinity binding to telomerase. It has been shown that
GRN163L causes telomerase inhibition and subsequent
telomere shortening in many cell types, including in breast
cancer, lung cancer, multiple myeloma and non-Hodgkin’s
lymphoma cell lines [6–8]. GRN163L has recently entered
into Phase I/II clinical trials in patients with chronic
lymphocytic leukaemia and some solid tumors such as in
lung and breast cancer. Despite being a promising thera-
peutic agent, inhibition of telomerase activity may lead to
side effects since germline cells, proliferating stem and
progenitor cells also exhibit telomerase activity. Thus
inhibition of telomerase could potentially cause a decline
or defect in regenerative capacity and organ homeostasis
[9].
Mesenchymal stem cells (MSCs) are multipotent cells
capable of self-renewal and differentiating into multiple
lineages such as osteocytes, adipocytes, chondrocytes,
myoblasts, cardiomyocytes [10–12]. MSCs are also prom-
ising agents for cell-based therapies due to their ability to
migrate in vivo to promote regeneration of damaged tissue,
treat inflammation, and promote angiogenesis without
inducing immune reaction in addition to the lack of ethical
concerns [13, 14]. Additionally, their high self-renewal
potential makes them strong candidates for stem cell gene
therapy treating acquired and inherited disorders and
restoring organ system functions, since tissue repair and
regeneration is made possible by the presence of adult stem
cells [15]. For the above reasons, the effects of telomerase-
targeting therapies on MSCs must be well defined. The
present study was undertaken to investigate the in vitro
effects of GRN163L on the self-renewal and differentiation
processes of MSCs.
Materials and Methods
Isolation and Culture of MSCs
MSCs were obtained from female, 9-week-old, 280–300 g
Sprague–Dawley rats. After the rats were sacrificed by
cervical dislocation, bone marrow a heterogeneous cell
population was collected from the femurs and tibias by
flushing with a 5 mL syringe containing 10% FBS
(HyClone, Logan, USA) in DMEM (HyClone). The cells
were cultured in plastic cell-culture dishes with MesenCult
medium (StemCell Technologies, Vancouver, Canada) with
a 20% supplement (StemCell Technologies) and a 1%
penicillin–streptomycin solution (HyClone) in a 5% CO2
incubator at 37°C. The next day, the media of the tissue
culture plates were changed and the nonadherent cells were
removed. The media of the cells were changed every
3 days, after washing with sterile 1x PBS. Our experimental
study protocol was approved by the Animal Ethics
Committee of Bilkent University (BILHADYEK). All the
animals received care according to the criteria outlined in
the Guide for the Care and Use of Laboratory Animals
prepared by the National Academy of Science of the USA,
and this study protocol complied with Bilkent University’s
guidelines on the humane care and use of laboratory
animals.
Experimental Groups
After 14 days of culture, the cells were trypsinized
(HyClone) and transferred to culture dishes for RNA and
protein isolation as well as for differentiation and telomer-
ase activity assays. One day after the transfer, GRN163L
(Geron Co., CA, USA) and its mismatch control oligo were
added at a concentration of 1 µM to the cell plate. The
media were changed every 3 days with the fresh GRN163L
(hereafter stated as 163 L group) and mismatch control
oligonucleotide (hereafter stated as mismatch group) to-
gether with control MSCs with no treatment (hereafter
stated as control group). 163 L and mismatch cultures
continued for 1 week. Finally, MSCs were left for recovery
for 1 week after GRN163L was removed (hereafter stated
as 163LR (recovery) group).
Total RNA Isolation and Reverse Transcription
MSCs were trypsinized and the total cellular RNA was
isolated from the precipitate by using the RNeasy Mini kit
(Qiagen, Hilden, Germany) according to the manufacturer’s
protocol, with additional DNase treatment. The cDNAs
were synthesized from the total RNA samples with the
DyNAmo cDNA synthesis kit (Finnzymes, Espoo, Finland)
according to the manufacturer’s protocol.
RT-PCR
cDNA amplification for CD90, CD71, CD45, CD34, CD29
and cyclophilin were performed by using DyNAzyme II
(Finnzymes). The primers are listed in Table 1. The initial
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denaturation step was at 95°C for 5 min, followed by 30
(for CD90 and CD34), 35 (for CD 71), 26 (for CD29 and
CD45) and 23 (for cyclophilin) cycles of denaturation for
30 s for all genes at 94°C, annealing for 30 s at 55°C (for
CD90, CD34 and cyclophilin), 60 s at 66°C (for CD71) and
30 s at 60°C (for CD29 and CD45), followed by extension
for 30 s (for CD90, CD34, CD29, CD45 and cyclophilin)
and 45 s (for CD71) at 72°C. A final extension at 72°C for
5 min was applied to all the reactions.
Q-RT-PCR
The primers used for Q- RT-PCR are shown in Table 1.
Before performing Q- RT-PCR reactions for experimental
samples, the amplification efficiencies of all primers were
calculated using a standard dilution series. Fold changes
in the expression of the genes were estimated based on
the comparative Ct 2ΔΔCt
 
method, using the normal
MSCs as calibrator. The Q- RT-PCR conditions for all
Gene Sequence Product size (bp)
TERT (F) 5′-GCTACGCCATCCTGAAGGTC-3′ 99
(R) 5′-GGTAGCAGAGCCAACGTGTG-3′
CYCLIN B1 (F) 5′-TCGATGTGGAGCAGCATACT-3′ 142
(R) 5′-GTCCATTCACCGTTGTCAAG-3′
CDK4 (F) 5′-GAAGACGACTGGCCTCGAGA-3′ 109
(R) 5′-ACTGCGCTCCAGATTCCTCC-3′
CDK6 (F) 5′-TTGTGACAGACATCGACGAG-3′ 151
(R) 5′-GACAGGTGAGAATGCAGGTT-3′
CDK2 (F) 5′-TGACCAACTCTTCCGGATCT-3′ 164
(R) 5′-ATAACAAGCTCCGTCCGTCT-3′
CDK1 (F) 5′-GTTGACATCTGGAGCATAGG-3′ 144
(R) 5′-CTCTACTTCTGGCCACACTT-3′
CYCLIN A2 (F) 5′-CTGCCTTCCACTTAGCTCTC-3′ 125
(R) 5′-GAGGTAGGTCTGGTGAAGGT-3′
RB (F) 5′-TTGAAAGAAGAGGCACTCCC-3′ 116
(R) 5′-CGCTACCTTAAATACCGCCT-3′
P53 (F) 5′-GTTCCGAGAGCTGAATGAGG-3′ 109
(R) 5′-AGACTGGCCCTTCTTGGTCT-3′
Bmi-1 (F) 5′-ATGTGTGTCCTGTGTGGAGG-3′ 281
(R) 5′-AGCCATTGGCAGCATCTGCT-3′
P21 (F) 5′-ATGTCCGATCCTGGTGATGTC-3′ 92
(R) 5′-CGGCTCAACTGCTCACTGTC-3′
Cdc25a (F) 5′-AGTGAAGAGAGCAGACCGAT-3′ 126
(R) 5′-GGAGAGAGACTGGTGTGGAA-3′
P16INK4a (F) 5′-CTTCACCAAACGCCCCGAACA-3′ 132
(R) 5′-CGGGAGAGGGTGGTGGGGTC-3′
P19ARF (F) 5′-GCAGAGCATGGGTCGCAGGTTC-3′ 295
(R)5′-CGGGAGAGGGTGGTGGGGTC-3′
CYCLIN D1 (F) 5′-AATGCCAGAGGCGGATGAGA-3′ 189
(R) 5′-GCTTGTGCGGTAGCAGGAGA-3′
CYCLIN E (F) 5′-TTACTGATGGTGCTTGCTCC-3′ 136
(R) 5′-GTCGTTGACGTAGGCCACTT-3′
Cyclophilin (F) 5′-GGGAAGGTGAAAGAAGGCAT-3′ 211
(R) 5′-GAGAGCAGAGATTACAGGGT-3′
CD 90 (F) 5′-CCAGTCATCAGCATCACTCT-3′ 374
(R) 5′-AGCTTGTCTCTGATCACATT-3′
CD 34 (F) 5′-TGTCTGCTCCTTGAATCT-3′ 281
(R) 5′-CCTGTGGGACTCCAACT-3′
CD 71 (F) 5′-ATGGTTCGTACAGCAGCAGA-3′ 182
(R) 5′-CGAGCAGAATACAGCCATTG-3′
CD 29 (F) 5′-ACTTCAGACTTCCGCATTGG-3′ 190
(R) 5′-GCTGCTGACCAACAAGTTCA-3′
CD 45 (F) 5′-ATGTTATTGGGAGGGTGCAA-3′ 175
(R) 5′-AAAATGTAACGCGCTTCAGG-3′
Table 1 Primer sequences for
Q-RT-PCR and RT-PCR and
product size
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investigated genes have an initial denaturation 95°C,
10 min followed by 45 cycles (for all target genes) and
35 cycles (for housekeeping cyclophilin) of denaturation
for 30 s at 94°C, annealing for 30 s at 60°C (for TERT,
cdk4, cyclin A and Bmi-1), at 55°C (for cyclin B1, cdk6,
cdk2, cdk1, RB, p21 and cyclophilin), at 65°C (for cyclin
D1 and p53), at 59°C (for cdc25A and cyclin E), at 62°C
(for p16INK4a), at 68°C (for p19ARF), followed by extension
of 30 s at 72°C. Final extension at 72°C for 5 min was
applied to all the reactions.
Protein Isolation and Quantification
MSCs were scraped from the cell culture plates in 1x PBS
and the precipitate was treated with a lysis buffer contain-
ing 0.05 M Tris HCl, 1x protease inhibitor, 0.25 M NaCl
and 1% (v/v) IGEPAL for 30 min on ice. Then the lysate
was centrifugated for 20 min at 13,000 rpm at 4°C. Protein
concentrations of supernatants were determined with
Bradford protein assay as described [16].
Western Blotting
The proteins were separated on 8% SDS-PAGE and
transferred to a polyvinylidene fluoride membrane. The
membrane was blocked with blocking solution for 1 h at
room temperature and was incubated in antibody solution at
the concentration of 1:200 (for Bmi-1, TERT, Cdc25a,
Cyclin A, Cdk4, Cyclin D1, Cyclin E), 1:1000 (for Cdk1,
Cdk2, Cyclin B1, p53), 1:2000 (for Cdk6, α-Tubulin) for o/
n at 4°C. Then horseradish peroxidase-linked secondary
antibodies were applied for 1 h in blocking solution.
Finally, Super Signal West Femto Maximum Sensitivity
Substrate (Thermo Scientific, IL, USA) was applied to the
membrane for 5 min and placed in an X-ray film cassette
and developed. Anti-Bmi-1, TERT, Cdc25a, Cyclin A,
Cdk4, Cyclin D1, and Cyclin E antibodies were purchased
from Santa Cruz (Santa Cruz, CA, USA). Anti-Cdk1, Cdk2,
Cyclin B1 and p53 antibodies were purchased from Cell
Signaling Technology (Danvers, MA, USA). Anti-α-Tubulin
antibody was purchased from Calbiochem (Darmstadt,
Germany).
Estimation of Telomerase Activity Using Telomeric Repeat
Amplification Protocol Assay (TRAP)
1×106 MSCs were collected by trypsinization and a
telomerase assay was performed by using TRAP-eze
Telomerase Detection Kit (Millipore, MA, USA). A gel-
based assay was performed for visualization of the
telomeric repeats after PCR, according to the manufac-
turer’s protocol. Gels were stained with SYBR Green I
(Sigma, MO, USA) at 1:10000 dilution in TAE and
visualized with Vilber Lourmat ChemiCapture (Marne-La-
Vallée Cedex, France).
Adipogenic Differentiation
An adipogenic induction medium was prepared by freshly
adding 1 µM dexamethasone (Sigma), 10 µg/ml insulin
(Sigma), 100 µM indomethacin (Sigma) and 0.5 mM
IBMX to LG-DMEM (HyClone), containing 1x penicillin-
streptomycin (HyClone) and 10% FBS (HyClone). The
MSCs were cultured for 21 days, changing the medium
every 2 days with freshly prepared medium. After 21 days
the cells were fixed with 4% paraformaldehyde and stained
with Oil Red O (Sigma).
Osteogenic Differentiation
An osteogenic induction medium was prepared by freshly
adding 0.1 µM dexamethasone (Sigma), 0.2 mM ascorbic
acid 2-phosphate (Sigma) and 10 mM glycerol-2-
phosphate (Sigma) to LG-DMEM (HyClone), containing
1x penicillin-streptomycin (HyClone) and 10% FBS
(HyClone). The MSCs were cultured for 21 days,
changing the medium every 2 days for freshly prepared
medium. After 21 days the cells were fixed with 70%
ethanol and stained with Alizarin Red S (Sigma).
Statistical Analysis
All data are expressed as means ± SD. Data were analyzed
by performing a paired t- test using Minitab Statistical
Software ® (State College, Pennsylvania, USA). A value of
P<0.05 was considered to be statistically significant.
Results
We first investigated the phenotypic effect of GRN163L on
MSCs (Fig. 1). Untreated control MSCs (Fig. 1a) and
mismatch oligonucleotide treated MSCs (Fig. 1b) showed
normal phenotypes with fibroblastic morphology and
spindle-shaped cells. At the same time, when MSCs were
plated in the presence of single dose of 1 μM GRN163L
(163L), we observed phenotypic effects as early as 3 days
after the treatment, such as the cells losing their fibroblastic
shapes, rounding up, and appearing to detach from the plate
surface (Fig. 1c). However, when the drug was removed
and the cells were given time to recover (163LR),
GRN163L-treated MSCs reattached to the plate surface
and regained their normal phenotype within 1 week
(Fig. 1d). By using RT-PCR, we showed that all of the
experimental groups were positive for mesenchymal stem
cell markers (CD29, CD71 and CD90) and negative for
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hematopoietic cell markers (CD34, CD45) (Fig. 1e). We
also examined telomerase activity of MSCs from control,
163L, mismatch and 163LR groups by the TRAP assay
(Fig. 2). The telomerase activity of the MSCs in the 163L
group was completely inhibited, whereas inhibition was not
observed in the mismatched, 163LR or control MSCs. The
effect of GRN163L on telomerase activity was reversible
because the telomeric repeats were also observed in the
163LR group with a similar pattern as in the untreated
control MSCs (Fig. 2a). No telomeric repeats were present
when cell extracts were heat inactivated (Fig. 2b).
To illustrate if after the removal of the ligand whether
MSCs regain their differentiation properties, we induced
lipidogenic (Fig. 3) and osteogenic (Fig. 4) differentiation
Fig. 1 The effect of GRN163L
a Untreated control MSCs
(control); b Mismatch
oligonucleotide treated MSCs
(mismatch); c 1 µM GRN163L
treated MSCs (163L); d MSCs
that were treated, and then left
for 1 week without the ligand
(163LR); e The expression
of the markers of MSCs
(CD90, CD29 and CD71) and
hematopoietic cells (CD34,
CD45)
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in 163LR and compared them to that of control group.
These results show that MSCs are able to differentiate into
adipocytes (Fig. 3c) and osteocytes (Fig. 4c) after they
recovered from the GRN163L treatment, similar to the
MSCs from the control group (Figs. 3a and 4a). We did not
observe differentiation of MSCs from control and 163LR
groups into adipocytes or osteocytes when these cells were
cultured in non-inducing media (Figs. 3b, d and 4b, d
respectively).
As the MSCs cease growing in the presence of
GRN163L and then regain their growth abilities when the
drug was removed, the expression of cell cycle genes
(cyclin A, B, D and E and their counterparts, cdk 1, 2, 4 and
6) were checked both at the mRNA with qRT-PCR (Fig. 5)
and protein level with Western blotting (Fig. 6). In addition,
cdc25A, p16, p19, p21, p53, RB, TERT and Bmi-1 levels
were also investigated. The expression of all the tested
genes were found to decrease upon 163L treatment,
compared to the control group at the mRNA level. Among
those genes, the decrease was statistically significant in the
expression of cyclin D1, cdk6, cyclin E, cyclin B1, cdc25A,
Bmi1, p21and p19 (Fig. 5; control vs 163L). Interestingly,
the expression of all the genes increased in the 163LR
group where the ligand was removed and the MSCs
recovered. Among these genes the increase was significant
in the expression of cdc25A, p53, p21 and p19 (Fig. 5;
163L vs 163LR). The effect of the ligand appears telomerase
Fig. 2 TRAP assay of MSCs from control, mismatched, 163L and
163LR groups. A549 lung cancer cell line was used as a positive
control to determine the telomerase inhibition by 163L. Cell extracts
were prepared from a normal and b heat inactivated samples
Fig. 3 Oil Red O staining
to determine adipogenic
differentiation of MSCs. a
control and c 163LR group by
using induction media. MSCs
from b control group and d
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inhibition specific, since the expression of these genes in the
mismatch group did not decrease (Fig. 5; 163L vs
mismatch). The expression of all the genes, except cyclin
B1 and RB, which were higher than the control group
(Fig. 5; control vs mismatch). A similar pattern of
expression, that is, to decrease upon the 163L treatment
and to increase 1 week after the removal of 163L was also
observed in the expression of some of these genes at the
protein level (Fig. 6). Our Western blot results showed that
the expression of Cdk2, Cdk4, Cdk6, Cyclin D1, and Bmi-
1 decreased in the 163L group compared to the control
group (Fig. 6; control vs 163L) and increased 1 week after
the removal of 163L (Fig. 6; 163L vs 163LR). In contrast,
the expression of Cyclin E and Cdc25A were similar in
control and 163L groups, however, they increased after
163L was removed (Fig. 6; 163L vs 163LR). Other
proteins that were tested did not show any difference
between the groups.
Fig. 4 Alizarin Red S staining
to determine osteogenic differ-
entiation of MSCs. a control
and c 163LR group by using
induction media. MSCs from
b control group and d 163LR




Fig. 5 mRNA expression of
cell cycle genes in MSCs from
control, mismatch, 163L and
163LR groups determined with
qRT-PCR. * indicates p≤0.05
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Discussion
The use of anti-telomerase agents as cancer therapeutic
agents is still in an early stage for complete analyses of
clinical outcomes, efficacy, tolerance and toxicity on
normal tissue [17]. Potential effects of the inhibition of
telomerase activity on stem cells are important because
different stem cell compartments have different levels of
telomerase activity [18]. Embryonic stem cells express high
levels of telomerase activity [19] while several adult stem
cell compartments, such as hematopoietic stem cells,
epidermal stem cells, neural stem cells and mesenchymal
stem cells also maintain telomerase activity but with low
levels [9, 18, 20].
Among these stem cells, the effect of telomerase
inhibitor GRN163L on mesenchymal stem cells is an issue
of potential concern when applied to tumor tissue in vivo
because MSCs emerge as an important player of cell-based
therapies in a wide variety of pathologies, including
cardiovascular disease and myocardial infarction (MI),
brain and spinal cord injury, cartilage and bone injury,
Crohn’s disease and graft-versus-host disease (GVHD)
during bone marrow transplantation [15, 21]. In vivo bone
formation potential of telomerase-over expressing hMSCs
was highly enhanced suggesting telomerase is required for
both cell replication and differentiation [22]. Moreover,
mouse MSCs with their telomerase activity knocked-down
completely failed to differentiate into adipocytes or chon-
drocytes [23]. Thus, one could speculate that hMSCs may
express at least a low level of telomerase activity to carry
out the regenerative capacity as well as the differentiation
potential [18]. Treatment with a telomerase inhibitor could
have unwanted side effects on MSCs. While the potential
side effects are unknown, they are expected to be mild
because stem cell populations have longer telomeres than
tumor cells, and as they divide rarely, their telomeres
should shorten at a much slower rate than proliferating
cancer cells [24].
The present study was undertaken to investigate the in
vitro effects of GRN163L on the self-renewal and differ-
entiation processes of MSCs. First, we evaluated the
morphological changes of MSCs upon treatment of
GRN163L. Previous studies have shown that rapid mor-
phological changes occur within 24 h in cancer cells when
plated in the presence of GRN163L and cells become
rounded up, loosely attached to the surface, cease growing
and die [25, 26]. These morphological changes were
independent of telomerase inhibitory effect of GRN163L
via hTR antagonism, but related to the lipidation of the
compound, the nitrogen-phosphorous-sulfur–containing
backbone chemistry (NPS linkage) and the presence of
triple-G motif. It has also been suggested that antimetastatic
effects of GRN163L may be related with the anti-cell
adhesive effects of this novel cancer therapeutic agent [25].
In our study, similar to the data reported for cancer cell
lines, we observed similar morphological changes when
MSCs were plated in the presence of GRN163L, suggesting
a similar mechanism of action of GRN163L both in MSCs
and cancer cells. The cells’ rounding effects were observed
within 24 h after GRN163L treatment (Fig. 1c), whereas
mismatch oligonucleotide-treated MSCs became tightly
attached to the cell culture plate, similar to the untreated
control cells (Fig. 1b and a, respectively). Moreover,
“rounding effect” was not observed when GRN163L was
withdrawn (163LR group) and they regained the original
mesenchymal stem cell morphology as the unreated control
group (Fig. 1d).
MSCs play an important role in the homeostasis of
organisms therefore GRN163L would not be predicted to
cause any alteration in the long term irreversible differen-
tiation potential of MSCs. To address this issue, we treated
MSCs with GRN163L, let them recover for 1 week and
then evaluated their osteogenic and adipogenic differ-
Fig. 6 Protein expression of cell cycle genes in MSCs from control,
163L and 163LR groups determined by Western blot
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entiations (Figs. 3 and 4, respectively). Our results showed
that there was no noticeable difference in the potential of
these MSCs to differentiate into adipocytes and osteocytes
when compared with the untreated control cells. Observing
of no measurable effects on the differentiation of MSCs
upon GRN163L treatment is of particular clinical impor-
tance, mainly for older patients. Aging deteriorates the
differentiation potential of MSCs [27, 28]; therefore to use
GRN163L for anti-cancer treatment of the elderly would
seem not further decrease the potential.
Several studies have examined telomerase activity in
MSCs, providing somewhat differing results. As discussed
in Sethe et al. 2006, some studies find no telomerase
activity in MSCs, whereas others have detected telomerase
activity [29]. Our results clearly showed that MSCs do have
telomerase activity, and the activity is inhibited by
GRN163L (Fig. 2). Importantly, telomerase activity recov-
ers upon withdrawal of GRN163L (Fig. 2; 163LR group).
The reason for this disparity could be explained by the
presence of the heterogeneous group of MSCs (telomerase
positive and negative) and it clearly warrants further
research [30, 31]. The difference could also be related to
the passage number of MSCs used. It has been recently
shown that telomerase activity is present at 10 days but
negative at 30 days [32]. The MSCs that were used in this
study derived from the first passage and were physiolog-
ically more relevant.
As the “rounded” MSCs were not able to proliferate as
much as the untreated cells, several cyclins and cdks that
regulate cell cycle were analyzed to determine whether
telomerase inhibition leads to cell cycle arrest. Our real-
time PCR and Western blot data clearly showed that
inhibiting telomerase activity with GRN163L does leads
to cell cycle arrest at the G1 phase, and that importantly,
these effects were reversible. Therefore, it is possible to
conclude that the MSCs will regain their proliferation and
self-renewal capacity following the cessation of anti-
telomerase therapy. Additionally, the mismatch oligonucle-
otide had no effect on the proliferation status of these cells,
indicating high specificity of this compound.
It is also important to note that the in vitro effects of
GRN163L on MSCs may not necessarily reflect their
possible in vivo effects. When the telomerase activity was
knocked down, mouse MSCs failed to differentiate into
adipocytes or chondrocytes [23]. On the other hand
telomerase-over expressing hMSCs had been shown to
have a high osteogenic differentiation potential [22].
Systemic effects of telomerase inhibition on bone marrow-
derived MSCs might be different than in vitro reversible
effects. Therefore, new studies are warranted to investigate
the role of GRN163L on in vivo conditions.
In summary, we have investigated the potential effects of
GRN163L on MSCs. Our results suggest that the inhibitory
effect of GRN163L on mesenchymal stem cells is revers-
ible in under short term in vitro cell culture conditions. We
conclude that hTR antagonist GRN163L does not interfere
with the self-renewal and differentiation of MSCs and can
be used without apparent toxic side effects. Nevertheless, in
clinical settings anti-telomerase cancer treatment should be
stopped before telomere depletion in stem cells, so that
telomerase activity and telomeres in reproductive and stem
cells can be restored. Our study provides additional support
for treating cancers by administrating GRN163L without
depleting the body’s stem cell pools.
Acknowledgements This study is supported by Tubitak (SBAG-
3200, 105S393) and Bilkent University . The authors would like to
thank Dr. Jerry W. Shay for critical reading and to Rana Nelson for
editorial reviewing of the manuscript.
References
1. Greider, C. W., & Blackburn, E. H. (1985). Identification of a
specific telomere terminal transferase activity in Tetrahymena
extracts. Cell, 43, 405–413.
2. Greider, C. W., & Blackburn, E. H. (2004). Tracking telomerase.
Cell, 116, 83–86.
3. Shay, J. W., & Wright, W. E. (2006). Telomerase therapeutics for
cancer: challenges and new directions. Nature Reviews Drug
Discovery, 5, 577–584.
4. Shay, J. W., & Keith, W. N. (2008). Targeting telomerase for
cancer therapeutics. British Journal of Cancer, 98, 677–683.
5. Keith, W. N., Thomson, C. M., Howcroft, J., Maitland, N. J., &
Shay, J. W. (2007). Seeding drug discovery: Integrating telomer-
ase cancer biology and cellular senescence to uncover new
therapeutic opportunities in targeting cancer stem cells. Drug
Discovery Today, 12, 15–16.
6. Gellert, G., Dikmen, Z., Wright, W. E., Gryaznov, S., & Shay, J.
W. (2006). Effects of a novel telomerase inhibitor, GRN163L, in
human breast cancer. Breast Cancer Research and Treatment, 96,
73–81.
7. Wang, E. S., Wu, K., Chin, A. C., et al. (2004). Telomerase
inhibition with an oligonucleotide telomerase template antagonist:
In vitro and in vivo studies in multiple myeloma and lymphoma.
Blood, 103, 258–266.
8. Dikmen, Z. G., Gellert, G. C., Jackson, S., et al. (2005). In vivo
inhibition of lung cancer by GRN163L: A novel human
telomerase inhibitor. Cancer Research, 65, 7866–7873.
9. Cong, Y., & Shay, J. W. (2008). Actions of human telomerase
beyond telomeres. Cell Research, 18, 725–732.
10. Friedenstein, A. J., Chailakhjan, R. K., & Lalykina, K. S. (1970).
The development of fibroblast colonies in monolayer cultures of
guinea-pig bone marrow and spleen cells. Cell and Tissue
Kinetics, 3, 393–403.
11. da Silva, M. L., Caplan, A. I., & Nardi, N. B. (2008). In search of
the in vivo identity of mesenchymal stem cells. Stem Cells, 26,
2287–2299.
12. Tokcaer-Keskin, Z., Akar, A. R., Ayaloglu-Butun, F., et al. (2009).
Timing of induction of cardiomyocyte differentiation for in vitro
cultured mesenchymal stem cells: A perspective for emergencies.
Canadian Journal of Physiology and Pharmacology, 87, 143–
150.
13. Karp, J. M., & Leng-Teo, G. S. (2009). Mesenchymal stem cell
homing: The devil is in the details. Cell Stem Cell, 4, 206–216.
232 Stem Cell Rev and Rep (2010) 6:224–233
14. Zipori, D. (2006). The mesenchyme in cancer therapy as a target
tumor component, effector cell modality and cytokine expression
vehicle. Cancer and Metastasis Reviews, 25, 459–467.
15. Reiser, J., Zhang, X. Y., Hemenway, C. S., Mondal, D., Pradhan,
L., & La Russa, V. F. (2005). Potential of mesenchymal stem cells
in gene therapy approaches for inherited and acquired diseases.
Expert Opinion on Biological Therapy, 5, 1571–1584.
16. Bradford, M. M. (1976). A rapid and sensitive method for the
quantification of microgram quantities of protein utilizing the
principle of protein-dye binding. Analytical Biochemistry, 74,
248–254.
17. Molckovsky, A., & Siu, L. L. (2008). First-in-class, first-in-human
phase I results of targeted agents: Highlights of the 2008
American Society of Clinical Oncology meeting. Journal of
Hematology and Oncology, 1, 20.
18. Serakinci, N., Graakjaer, J., & Kolvraa, S. (2008). Telomere
stability and telomerase in mesenchymal stem cells. Biochimie,
90, 33–40.
19. Carpenter, M. K., Rosler, E. S., Fisk, G. J., et al. (2004).
Properties of four human embryonic stem cell lines maintained in
a feeder-free culture system. Developmental Dynamics, 229, 243–
258.
20. Flores, I., Benetti, R., & Blasco, M. A. (2006). Telomerase
regulation and stem cell behaviour. Current Opinion in Cell
Biology, 18, 254–260.
21. Phinney, D. G., & Prockop, D. J. (2007). Concise review:
Mesenchymal stem/multipotent stromal cells: The state of trans-
differentiation and modes of tissue repair–current views. Stem
Cells, 25, 2896–2902.
22. Simonsen, J. L., Rosada, C., Serakinci, N., et al. (2002).
Telomerase expression extends the proliferative life-span and
maintains the osteogenic potential of human bone marrow stromal
cells. Nature Biotechnology, 20, 592–596.
23. Liu, L., DiGirolamo, C. M., Navarro, P. A., Blasco, M. A., & Keefe,
D. L. (2004). Telomerase deficiency impairs differentiation of
mesenchymal stem cells. Experimental Cell Research, 294, 1–8.
24. Shay, J. W., & Wright, W. E. (2007). Hallmarks of telomeres in
ageing research. Journal of Pathology, 211, 114–123.
25. Jackson, S. R., Zhu, C. H., Paulson, V., et al. (2007). Anti-
adhesive effects of GRN163L—an oligonucleotide N3′ → P5′
thiophosphoramidate targeting telomerase. Cancer Research, 67,
1121–1129.
26. Goldblatt, E. M., Gentry, E. R., Fox, M. J., Gryaznov, S. M.,
Shen, C., & Herbert, B. S. (2009). The telomerase template
antagonist GRN163L alters MDA-MB-231 breast cancer cell
morphology, inhibits growth, and augments the effects of
paclitaxel. Molecular Cancer Therapeutics, 8, 2027–2035.
27. Stenderup, K., Justesen, J., Clausen, C., & Kassem, M. (2003).
Aging is associated with decreased maximal life span and
accelerated senescence of bone marrow stromal cells. Bone, 33,
919–926.
28. Kretlow, J. D., Jin, Y. Q., Liu, W., et al. (2008). Donor age and
cell passage affects differentiation potential of murine bone
marrow-derived stem cells. BMC Cell Biology, 9, 60–72.
29. Sethe, S., Scutt, A., & Stolzing, A. (2006). Aging of mesenchymal
stem cells. Ageing Research Reviews, 5, 91–116.
30. Schieker, M., Pautke, C., Reitz, K., et al. (2004). The use of four-
colour immunofluorescence techniques to identify mesenchymal
stem cells. Journal of Anatomy, 204, 133–139.
31. Zimmermann, S., Voss, M., Kaiser, S., Kapp, U., Waller, C. F., &
Martens, U. M. (2003). Lack of telomerase activity in human
mesenchymal stem cells. Leukemia, 17, 1146–1149.
32. Galderisi, U., Helmbold, H., Squillaro, T., et al. (2009). In vitro
senescence of rat mesenchymal stem cells is accompanied by
downregulation of stemness-related and DNA damage repair
genes. Stem Cells and Development, 18, 1–9.
Stem Cell Rev and Rep (2010) 6:224–233 233
